Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 26

1.

Pneumonia and Renal Replacement Therapy Are Risk Factors for Ceftazidime-Avibactam Treatment Failures and Resistance among Patients with Carbapenem-Resistant Enterobacteriaceae Infections.

Shields RK, Nguyen MH, Chen L, Press EG, Kreiswirth BN, Clancy CJ.

Antimicrob Agents Chemother. 2018 Apr 26;62(5). pii: e02497-17. doi: 10.1128/AAC.02497-17. Print 2018 May.

2.

Verification of Ceftazidime-Avibactam and Ceftolozane-Tazobactam Susceptibility Testing Methods against Carbapenem-Resistant Enterobacteriaceae and Pseudomonas aeruginosa.

Shields RK, Clancy CJ, Pasculle AW, Press EG, Haidar G, Hao B, Chen L, Kreiswirth BN, Nguyen MH.

J Clin Microbiol. 2018 Jan 24;56(2). pii: e01093-17. doi: 10.1128/JCM.01093-17. Print 2018 Feb.

3.

Ceftolozane-Tazobactam for the Treatment of Multidrug-Resistant Pseudomonas aeruginosa Infections: Clinical Effectiveness and Evolution of Resistance.

Haidar G, Philips NJ, Shields RK, Snyder D, Cheng S, Potoski BA, Doi Y, Hao B, Press EG, Cooper VS, Clancy CJ, Nguyen MH.

Clin Infect Dis. 2017 Jul 1;65(1):110-120. doi: 10.1093/cid/cix182.

4.

Emergence of Ceftazidime-Avibactam Resistance and Restoration of Carbapenem Susceptibility in Klebsiella pneumoniae Carbapenemase-Producing K pneumoniae: A Case Report and Review of Literature.

Shields RK, Nguyen MH, Press EG, Chen L, Kreiswirth BN, Clancy CJ.

Open Forum Infect Dis. 2017 Jul 1;4(3):ofx101. doi: 10.1093/ofid/ofx101. eCollection 2017 Summer.

5.

Ceftazidime-Avibactam Is Superior to Other Treatment Regimens against Carbapenem-Resistant Klebsiella pneumoniae Bacteremia.

Shields RK, Nguyen MH, Chen L, Press EG, Potoski BA, Marini RV, Doi Y, Kreiswirth BN, Clancy CJ.

Antimicrob Agents Chemother. 2017 Jul 25;61(8). pii: e00883-17. doi: 10.1128/AAC.00883-17. Print 2017 Aug.

6.

Whole-Genome Sequencing Accurately Identifies Resistance to Extended-Spectrum β-Lactams for Major Gram-Negative Bacterial Pathogens.

Shelburne SA, Kim J, Munita JM, Sahasrabhojane P, Shields RK, Press EG, Li X, Arias CA, Cantarel B, Jiang Y, Kim MS, Aitken SL, Greenberg DE.

Clin Infect Dis. 2017 Sep 1;65(5):738-745. doi: 10.1093/cid/cix417.

7.

In Vitro Selection of Meropenem Resistance among Ceftazidime-Avibactam-Resistant, Meropenem-Susceptible Klebsiella pneumoniae Isolates with Variant KPC-3 Carbapenemases.

Shields RK, Nguyen MH, Press EG, Chen L, Kreiswirth BN, Clancy CJ.

Antimicrob Agents Chemother. 2017 Apr 24;61(5). pii: e00079-17. doi: 10.1128/AAC.00079-17. Print 2017 May.

8.

Emergence of Ceftazidime-Avibactam Resistance Due to Plasmid-Borne blaKPC-3 Mutations during Treatment of Carbapenem-Resistant Klebsiella pneumoniae Infections.

Shields RK, Chen L, Cheng S, Chavda KD, Press EG, Snyder A, Pandey R, Doi Y, Kreiswirth BN, Nguyen MH, Clancy CJ.

Antimicrob Agents Chemother. 2017 Feb 23;61(3). pii: e02097-16. doi: 10.1128/AAC.02097-16. Print 2017 Mar.

9.

Clinical Outcomes, Drug Toxicity, and Emergence of Ceftazidime-Avibactam Resistance Among Patients Treated for Carbapenem-Resistant Enterobacteriaceae Infections.

Shields RK, Potoski BA, Haidar G, Hao B, Doi Y, Chen L, Press EG, Kreiswirth BN, Clancy CJ, Nguyen MH.

Clin Infect Dis. 2016 Dec 15;63(12):1615-1618. Epub 2016 Sep 13.

10.

Rapid Detection of FKS-Associated Echinocandin Resistance in Candida glabrata.

Zhao Y, Nagasaki Y, Kordalewska M, Press EG, Shields RK, Nguyen MH, Clancy CJ, Perlin DS.

Antimicrob Agents Chemother. 2016 Oct 21;60(11):6573-6577. doi: 10.1128/AAC.01574-16. Print 2016 Nov.

11.

Evaluation of the In Vitro Activity of Ceftazidime-Avibactam and Ceftolozane-Tazobactam against Meropenem-Resistant Pseudomonas aeruginosa Isolates.

Buehrle DJ, Shields RK, Chen L, Hao B, Press EG, Alkrouk A, Potoski BA, Kreiswirth BN, Clancy CJ, Nguyen MH.

Antimicrob Agents Chemother. 2016 Apr 22;60(5):3227-31. doi: 10.1128/AAC.02969-15. Print 2016 May.

12.

Aminoglycosides for Treatment of Bacteremia Due to Carbapenem-Resistant Klebsiella pneumoniae.

Shields RK, Clancy CJ, Press EG, Nguyen MH.

Antimicrob Agents Chemother. 2016 Apr 22;60(5):3187-92. doi: 10.1128/AAC.02638-15. Print 2016 May.

13.

Erratum for Shields et al., Rate of FKS Mutations among Consecutive Candida Isolates Causing Bloodstream Infection.

Shields RK, Nguyen MH, Press EG, Cumbie R, Driscoll E, Pasculle AW, Clancy CJ.

Antimicrob Agents Chemother. 2016 Feb 26;60(3):1954. doi: 10.1128/AAC.00183-16. Print 2016 Mar. No abstract available.

14.

Rate of FKS Mutations among Consecutive Candida Isolates Causing Bloodstream Infection.

Shields RK, Nguyen MH, Press EG, Cumbie R, Driscoll E, Pasculle AW, Clancy CJ.

Antimicrob Agents Chemother. 2015 Dec;59(12):7465-70. doi: 10.1128/AAC.01973-15. Epub 2015 Sep 21. Erratum in: Antimicrob Agents Chemother. 2016 Mar;60(3):1954.

15.

Effects of Klebsiella pneumoniae carbapenemase subtypes, extended-spectrum β-lactamases, and porin mutations on the in vitro activity of ceftazidime-avibactam against carbapenem-resistant K. pneumoniae.

Shields RK, Clancy CJ, Hao B, Chen L, Press EG, Iovine NM, Kreiswirth BN, Nguyen MH.

Antimicrob Agents Chemother. 2015 Sep;59(9):5793-7. doi: 10.1128/AAC.00548-15. Epub 2015 Jul 13.

16.

Doripenem MICs and ompK36 porin genotypes of sequence type 258, KPC-producing Klebsiella pneumoniae may predict responses to carbapenem-colistin combination therapy among patients with bacteremia.

Shields RK, Nguyen MH, Potoski BA, Press EG, Chen L, Kreiswirth BN, Clarke LG, Eschenauer GA, Clancy CJ.

Antimicrob Agents Chemother. 2015 Mar;59(3):1797-801. doi: 10.1128/AAC.03894-14. Epub 2014 Dec 22.

17.

KPC-producing Klebsiella pneumoniae strains that harbor AAC(6')-Ib exhibit intermediate resistance to amikacin.

Bremmer DN, Clancy CJ, Press EG, Almaghrabi R, Chen L, Doi Y, Nguyen MH, Shields RK.

Antimicrob Agents Chemother. 2014 Dec;58(12):7597-600. doi: 10.1128/AAC.03831-14. Epub 2014 Oct 6.

18.

Abdominal candidiasis is a hidden reservoir of echinocandin resistance.

Shields RK, Nguyen MH, Press EG, Clancy CJ.

Antimicrob Agents Chemother. 2014 Dec;58(12):7601-5. doi: 10.1128/AAC.04134-14. Epub 2014 Oct 6.

19.

Carbapenem-resistant Klebsiella pneumoniae strains exhibit diversity in aminoglycoside-modifying enzymes, which exert differing effects on plazomicin and other agents.

Almaghrabi R, Clancy CJ, Doi Y, Hao B, Chen L, Shields RK, Press EG, Iovine NM, Townsend BM, Wagener MM, Kreiswirth B, Nguyen MH.

Antimicrob Agents Chemother. 2014 Aug;58(8):4443-51. doi: 10.1128/AAC.00099-14. Epub 2014 May 27.

20.

In vitro responses of Acinetobacter baumannii to two- and three-drug combinations following exposure to colistin and doripenem.

Oleksiuk LM, Nguyen MH, Press EG, Updike CL, O'Hara JA, Doi Y, Clancy CJ, Shields RK.

Antimicrob Agents Chemother. 2014;58(2):1195-9. doi: 10.1128/AAC.01779-13. Epub 2013 Nov 18.

21.

Anidulafungin and micafungin MIC breakpoints are superior to that of caspofungin for identifying FKS mutant Candida glabrata strains and Echinocandin resistance.

Shields RK, Nguyen MH, Press EG, Updike CL, Clancy CJ.

Antimicrob Agents Chemother. 2013 Dec;57(12):6361-5. doi: 10.1128/AAC.01451-13. Epub 2013 Sep 23.

22.

Caspofungin MICs correlate with treatment outcomes among patients with Candida glabrata invasive candidiasis and prior echinocandin exposure.

Shields RK, Nguyen MH, Press EG, Updike CL, Clancy CJ.

Antimicrob Agents Chemother. 2013 Aug;57(8):3528-35. doi: 10.1128/AAC.00136-13. Epub 2013 May 13.

23.

The presence of an FKS mutation rather than MIC is an independent risk factor for failure of echinocandin therapy among patients with invasive candidiasis due to Candida glabrata.

Shields RK, Nguyen MH, Press EG, Kwa AL, Cheng S, Du C, Clancy CJ.

Antimicrob Agents Chemother. 2012 Sep;56(9):4862-9. doi: 10.1128/AAC.00027-12. Epub 2012 Jul 2.

24.

Performance of Candida real-time polymerase chain reaction, β-D-glucan assay, and blood cultures in the diagnosis of invasive candidiasis.

Nguyen MH, Wissel MC, Shields RK, Salomoni MA, Hao B, Press EG, Shields RM, Cheng S, Mitsani D, Vadnerkar A, Silveira FP, Kleiboeker SB, Clancy CJ.

Clin Infect Dis. 2012 May;54(9):1240-8. doi: 10.1093/cid/cis200. Epub 2012 Mar 19.

PMID:
22431804
25.

The combination of doripenem and colistin is bactericidal and synergistic against colistin-resistant, carbapenemase-producing Klebsiella pneumoniae.

Jernigan MG, Press EG, Nguyen MH, Clancy CJ, Shields RK.

Antimicrob Agents Chemother. 2012 Jun;56(6):3395-8. doi: 10.1128/AAC.06364-11. Epub 2012 Mar 19.

26.

Five-minute exposure to caspofungin results in prolonged postantifungal effects and eliminates the paradoxical growth of Candida albicans.

Shields RK, Nguyen MH, Press EG, Clancy CJ.

Antimicrob Agents Chemother. 2011 Jul;55(7):3598-602. doi: 10.1128/AAC.00095-11. Epub 2011 May 2.

Supplemental Content

Loading ...
Support Center